Form 4: IGM Biosciences Director Acquires Shares as Part of Compensation Plan

Director Jakob Haldor Topsoe acquired 1,734 shares of IGM Biosciences common stock as part of a quarterly retainer, while also indirectly holding a significant number of shares through Topsoe Holding A/S.

Summary

• On December 31, 2024, Jakob Haldor Topsoe, a director of IGM Biosciences, acquired 1,734 shares of common stock.
• The acquisition was part of a quarterly retainer paid in common stock under the Issuer's Outside Director Compensation Policy.
• These shares were acquired as fully vested restricted stock units (RSUs), with each RSU representing the right to receive one share of IGM Biosciences common stock.
• Following the transaction, Topsoe directly owns 90,056 shares.
• Topsoe also indirectly holds 10,400,564 shares through Topsoe Holding A/S, where he and other board members may be deemed to share voting and investment power.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It reflects a routine transaction related to director compensation. There is no indication of significant positive or negative implications for the company.

Positives

• The acquisition of shares by a director can be seen as a positive sign, indicating confidence in the company's future.
• The use of RSUs as part of the director's compensation aligns the director's interests with those of the shareholders.

Industry Context

Director share acquisitions are common in the biotechnology industry as part of compensation packages to align management interests with shareholder value. This filing is a routine disclosure required by the SEC.

Comparison to Industry Standards

• Director compensation packages often include stock options, restricted stock units, and other equity-based awards.
• Companies like Amgen, Gilead Sciences, and Biogen also utilize similar compensation strategies to incentivize their directors and executives.
• The specific number of shares acquired and the terms of the RSUs are typical for director compensation in similarly sized biotech companies.

Stakeholder Impact

• The transaction has a minor positive impact on shareholders as it aligns the director's interests with the company's performance.

Key Dates